Evidence map›Paper›PMID 37969936›Full record

ArticleClinical nutrition research2023

The Effect of Vit-D Supplementation on the Side Effect of BioNTech, Pfizer Vaccination and Immunoglobulin G Response Against SARS-CoV-2 in the Individuals Tested Positive for COVID-19: A Randomized Control Trial.

Hawal Lateef Fateh, Goran Kareem, Shahab Rezaeian, Jalal Moludi, Negin Kamari

Registry-linked trialOpen access · diamondAbstract read
In one paragraph

Article in Clinical nutrition research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05851313 (Role of Anthropometric Indices and Vit-D Supplementation on BioNTech, Pfizer Vaccine Side Effect and Immunoglobulin G Response Against SARS-CoV-2 in Individuals Infected With COVID-19; A Randomized Control Trial), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05851313 phase3completednot on this map

Role of Anthropometric Indices and Vit-D Supplementation on BioNTech, Pfizer Vaccine Side Effect and Immunoglobulin G Response Against SARS-CoV-2 in Individuals Infected With COVID-19; A Randomized Control Trial

TypeinterventionalSponsorSulaimani Polytechnic UniversityRan2022 to 2023Enrolled500ConditionsCOVID-19 Respiratory InfectionArmsVitamin-D
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Hawal Lateef FatehNursing Department, Kalar Technical College, Garmian Polytechnic University, Kalar 46021, Iraq.ORCID https://orcid.org/0000-0003-3808-6404
Goran KareemMedical Laboratory Technology, Kalar Technical College, Garmian Polytechnic University, Kalar 46021, Iraq.ORCID https://orcid.org/0009-0003-2098-7826
Shahab RezaeianInfectious Diseases Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran.ORCID https://orcid.org/0000-0002-5094-5315
Jalal MoludiSchool of Nutrition Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran .ORCID https://orcid.org/0000-0002-8333-414X
Negin KamariSchool of Nutrition Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran .ORCID https://orcid.org/0000-0001-7734-3114
Kermanshah University of Medical Sciences · IRDuhok Polytechnic University · IQKurdistan Regional Government · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Vitamin D participates in the biological function of the innate and adaptive immune system and inflammation. We aim to specify the effectiveness of the vitamin D supplementation on the side effects BioNTech, Pfizer vaccination, and immunoglobulin G response against severe acute respiratory syndrome coronavirus 2 in subjects tested positive for coronavirus disease 2019 (COVID-19). Methods: In this multi-center randomized clinical trial, 498 people tested positive for COVID-19 were divided into 2 groups, receiving vitamin D capsules or a placebo (1 capsule daily, each containing 600 IU of vitamin D) over 14-16 weeks. Anthropometric indices and biochemical parameters were measured before and after the second dose of vaccination. Result: Fourteen to 16 weeks after supplementation, the intervention group had an immunoglobulin G (IgG) increase of 10.89 ± 1.2 g/L, while the control group had 8.89 ± 1.3 g/L, and the difference was significant between both groups (p = 0.001). After the second dose of vaccination, the supplement group significantly increased their 25-hydroxy vitamin D from initially 28.73 ± 15.6 ng/mL and increased to 46.48 ± 27.2 ng/mL, and the difference between them was significant. Those with a higher body mass index (BMI) had the most of symptoms, and the difference of side effects according to BMI level was significantly different. In 8 weeks after supplementation obese participants had the lowest IgG levels than overweight or normal subjects. The proportion of all types of side effects on the second dose was significantly diminished compared with the first dose in the intervention group. Conclusion: Supplementation of 600 IU of vitamin D3 can reduce post-vaccination side effects and increase IgG levels in participants who received BioNTech, Pfizer vaccine. Trial Registration: ClinicalTrials.gov Identifier: NCT05851313.

Indexed as

COVID-19 vaccineImmunoglobulin GSide effectsVitamin D

Identifiers

PMID37969936
PMCPMC10641329
OpenAlexW4388306892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.